A seller should treat a retrade as a decision process, not an automatic concession. First, ask the buyer to identify each requested change, the evidence behind it, and whether it reflects a newly discovered risk, a changed assumption, or a negotiation tactic. Then test the finding against source records, assess whether it can be cured, and compare revised economics with the cost and risk of continuing. The LOI, confidentiality agreement, exclusivity terms, and applicable law may affect what each party can do, so qualified transaction counsel should review those documents. Keep discussions focused, document responses, protect confidential information, and set a clear stopping point if the buyer will not substantiate the request.
Start by separating a finding from a request
A retrade is a buyer request to change discussed economics or terms after the parties have invested in the process, often after diligence. The label alone does not tell you whether the request is justified. Separate the underlying fact from the remedy the buyer wants.
Ask for a written schedule stating the issue, source document or analysis, claimed financial or operational effect, proposed change, and response deadline. A buyer who identifies a specific contract, liability, accounting item, customer issue, or other documented matter is presenting a diligence question. A broad assertion about risk needs a different response. It may deserve attention, but it is not yet a verified basis for changing price or structure.
Use a simple status for each item: confirmed, disputed, explainable, curable, or unresolved. Keep the buyer wording, source record, response, and open question together. This prevents a general concern from becoming an unexplained concession and gives counsel and advisers a consistent record.
Test whether the evidence changes the deal case
Financial due diligence is intended to help buyers and sellers make informed decisions, identify risks, test the deal hypothesis, and support valuation. [1] That does not mean every observation changes value. Ask what assumption the finding changes and whether the effect is recurring, one-time, timing-related, already disclosed, or capable of correction.
Reconcile the buyer calculation to source-of-truth records. Depending on the issue, those records may include signed contracts, general-ledger detail, tax filings, payroll records, customer agreements, inventory reports, permits, insurance files, or correspondence. Check the period, definition, treatment, and adjustments. A difference can arise from a legitimate interpretation of normalized earnings or working capital, but the parties should state that interpretation rather than hide it inside a revised headline price.
Quantify only what the records support. If the effect cannot yet be quantified, describe the uncertainty and identify the next document or expert review needed. Do not manufacture precision to preserve momentum. A clear unresolved item is more useful than an unsupported number.
Choose a response that matches the problem
A supported finding can call for more than a lower price. Possible responses include correcting the issue before closing, narrowing an affected representation, adding a defined closing condition, changing the form or timing of consideration, using a narrowly drafted escrow or indemnity, or agreeing a post-closing adjustment mechanism. The appropriate choice depends on the documents, governing law, transaction structure, and bargaining position.
The ABA describes how diligence findings may affect purchase-price mechanics, closing conditions, holdbacks, indemnification, or treatment of a contract that cannot be assigned. [2] That is a menu for discussion with counsel, not a universal list of remedies. Do not accept a broad reduction when a defined cure or limited protection addresses the actual risk, but do not insist on price certainty where evidence shows a material unresolved exposure.
If the concern is explainable, provide the explanation and supporting record in a controlled response. If curable, state the owner, action, completion evidence, and date. If disputed, state competing interpretations and propose focused review. If real but allocation cannot be agreed, decide whether the revised risk-adjusted deal still meets the seller's objectives.
Read the LOI and process documents before committing
An LOI may describe proposed commercial terms while making selected provisions binding. One SEC-filed LOI expressly separates nonbinding transaction terms from provisions concerning confidentiality, expenses, announcements, exclusivity, and dispute resolution. [3] It is an example of drafting, not a universal rule. Wording, governing law, transaction structure, and party conduct can matter.
Have qualified transaction counsel review the LOI, exclusivity or no-shop provision, nondisclosure agreement, process letters, and later amendments. Confirm whether the request triggers a notice, consultation, information-return, standstill, exclusivity, or dispute process. Do not assume that a nonbinding price statement means every part of the document is nonbinding, or that exclusivity prevents all alternatives in every jurisdiction.
Keep the commercial response separate from legal conclusions. You can say an item is unsupported, propose a meeting, or reserve your position while counsel evaluates rights and obligations. Avoid threats, admissions, or new promises in informal messages. Put agreed changes into a signed amendment or definitive document reviewed by counsel.
Protect information while the deal is unsettled
A retrade can create pressure to disclose more information quickly. More disclosure does not automatically resolve the dispute. Release only what is permitted and necessary for the defined diligence question, using the confidentiality and data-room rules already agreed.
The FTC warns that parties remain independent businesses until a transaction closes and should safeguard competitively sensitive information during negotiations and diligence. Its guidance recommends limiting information to what is needed, using aggregation or redaction, and considering clean teams or third-party consultants where sensitive information must be reviewed. [4] These precautions are especially important when the buyer competes with the seller, but the right process depends on the facts and applicable law.
Assign one owner to approve uploads and one human reviewer to check that each disclosure answers a documented question. Maintain an access record if the process provides one, and record return or destruction requirements if the deal stops. Do not upload confidential deal files to an AI tool unless permissions, retention, and approved use have been checked. AI may organize an owner-approved issue list, but a human must verify every factual statement and decide what may be shared.
Compare continuing with stopping
Decide in advance what would cause a pause, reset, or termination of discussions. Useful stopping conditions include an unsupported request after a defined evidence deadline, repeated scope expansion without a material new issue, refusal to follow the confidentiality process, or revised economics that no longer justify the seller's risk and opportunity cost. These are decision rules, not predictions about buyer intent.
Compare three paths: continue on current terms, continue with a targeted adjustment, or stop and preserve other options if permitted. Consider cash at closing, contingent consideration, execution risk, management distraction, confidentiality exposure, financing uncertainty, and the time needed to restart. Do not count an alternative buyer or outcome unless supported by an actual current process record. An earlier indication of interest is not a committed alternative.
If continuing, send a short written term sheet for disputed points and list what remains open. If pausing, identify the information or approval needed to resume. If stopping, follow notice, confidentiality, exclusivity, and destruction provisions that apply. A calm documented decision is stronger than an improvised concession made only to avoid an uncomfortable conversation.
Use a human-reviewed response workflow
A practical workflow has five checkpoints. The deal owner logs the request without removing qualifiers. The finance or operations owner maps each claim to a source record and checks period and calculation. Counsel reviews document rights, confidentiality, and proposed protections. The owner chooses a response and stopping condition. A human approver reviews the final communication against the evidence before it is sent.
If software or AI is used, define the source-of-truth folder, permitted users, task boundary, and review record before a pilot. A suitable pilot might classify buyer questions and draft an internal evidence checklist. It should not contact the buyer, negotiate, approve a concession, or disclose a file. Stop the pilot if it invents a source, merges separate issues, exposes restricted material, or cannot show which record supports a suggested statement.
Acquivo is a software platform that delivers the entire sell-side M&A process, valuation, marketing materials, buyer matching, and deal management, on one platform for business owners, M&A attorneys, and boutique investment banks. Acquivo gives business owners the entire sell-side process an investment bank would run, as software, with no success fee. The software is user-operated. Owners and authorized advisers remain responsible for evidence checks, permissions, negotiations, approvals, and legal review.
Key Points
- Require a written explanation and source record for every requested change.
- Reconcile the buyer calculation to relevant source records before discussing remedies.
- Match the remedy to the risk: cure, targeted protection, structure change, price change, or no change.
- Have counsel review the LOI, confidentiality terms, exclusivity, and amendments because enforceability is document- and jurisdiction-dependent.
- Set human-owned stopping conditions and do not let software send, negotiate, approve, or disclose on its own.
Sources and references
Source retrieval dates record research access, not article publication. Read our editorial and date policy.
- [1] Financial due diligence, Corporate Finance Faculty Best-Practice Guideline 71 · Accessed
- [2] Conducting Legal Due Diligence in M&A Transactions · Accessed
- [3] Non-Binding Letter of Intent, Cynergi Holdings, Inc. · Accessed
- [4] Avoiding antitrust pitfalls during pre-merger negotiations and due diligence · Accessed
Choose your next step
Acquivo is user-operated software. Owners and their professionals remain responsible for decisions, communications, and professional review.
Educational information, not individual legal, tax, or investment advice. Consult qualified professionals for your circumstances. Acquivo provides software, not representation or negotiation on your behalf.